Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study

BACKGROUND: Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. We assessed the impact of maraviroc treatment in persons living with HIV on subclinical indicators of atherosclerosis. METHODS: Per...

Descripción completa

Detalles Bibliográficos
Autores principales: Francisci, Daniela, Pirro, Matteo, Schiaroli, Elisabetta, Mannarino, Massimo R, Cipriani, Sabrina, Bianconi, Vanessa, Alunno, Alessia, Bagaglia, Francesco, Bistoni, Onelia, Falcinelli, Emanuela, Bury, Loredana, Gerli, Roberto, Mannarino, Elmo, De Caterina, Raffaele, Baldelli, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446135/
https://www.ncbi.nlm.nih.gov/pubmed/30968058
http://dx.doi.org/10.1093/ofid/ofz112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446135/
https://www.ncbi.nlm.nih.gov/pubmed/30968058
http://dx.doi.org/10.1093/ofid/ofz112

Ejemplares similares